Scientific Reference
Retatrutide (LY3437943)
Evidence profile: Human Phase 3 evidence
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist with activity at the GLP-1, GIP and glucagon receptors. Its design combines incretin-axis signalling through GLP-1 and GIP with glucagon receptor activity, a combination studied for its effects on energy balance in published metabolic research. Retatrutide is not an approved medicine in the United Kingdom or elsewhere and remains in clinical development by its originator. Supplied strictly as a research compound for laboratory use.
Published Research
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM et al. · The New England journal of medicine · 2023 · Clinical
PMID 37366315 — View on PubMedEfficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
Bajaj HS et al. · Lancet (London, England) · 2026 · Clinical
PMID 42250575 — View on PubMedRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Rosenstock J et al. · Lancet (London, England) · 2023 · Clinical
PMID 37385280 — View on PubMedLY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Urva S et al. · Lancet (London, England) · 2022 · Clinical
PMID 36354040 — View on PubMedEfficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis
Tewari J et al. · Expert review of clinical pharmacology · 2025 · Review
PMID 39817343 — View on PubMedEfficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials
Misra S et al. · Journal of basic and clinical physiology and pharmacology · 2025 · Review
PMID 40728138 — View on PubMed